May 12, 2006 -- Threshold Pharma was crushed today after revealing it put on hold its trial for a benign prostatic hyperplasia drug because of liver side effects; Senesco said that its RNAi therapy reduced inflammation and inhibited apoptosis in mice; courts reaffirmed lower court rulings in the stent battle between Cordis and Boston Scientific; Celera published data describing two new genetic markers for increased heart attack risk; Biovest won Fast-Track status for BiovaxID, a personalized immunotherapy for lymphoma; Osiris Therapeutics, a stem cell company, filed to make its IPO; BioMimetic priced its IPO at $8, a 33% hair cut; Barr Pharma received a non-final rejection notice from the US Patent office for Seasonale, its extended-cycle oral contraceptive; GlaxoSmithKline will add a suicide warning to its Paxil label; and Biosite is facing a delay in approval of its blood test for strokes. The Centient Biotech 200™ sank 27 points to 3678.14, a .72% drop. More details...
